Navigation Links
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
Date:3/17/2008

nds in a glucose tolerance test in mice. In Q4 2006, MTI implemented a chemical design and synthesis program which led to the submission of a patent application in February 2008 claiming two novel lead series of AMPK activators.

MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.

For further information:

Mercury Therapeutics Inc.

Neil C Birnberg, Ph.D, President & CEO Tel: + 1-781-932-1125

birnberg@mtipharm.com http://www.mtipharm.com


'/>"/>
SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...rstCall/ -- BioSpecifics Technologies Corp. (Nasda... first-in-class collagenase-based products, today ...ter ended September 30, 2009. ,, "We were extr...DA,s Arthritis Advisory Committee unanimously reco...X(TM) for the treatment of Dupuytren,s disease, an...
(Date:11/6/2009)...-FirstCall/ -- ,, 3Q09 Corporate Highlights:...arketing Authorization to Astellas Pharma Europe L...iness activities Expanded management team to incl...ctor, Commercial Operations Appointed Bradford S....chairman , Upcoming 2009 Milestones: ,...
(Date:11/6/2009)...rowhead’s 2010 Personalized Medicine Partner...bruary 22-24, 2010 in Philadelphia, has been annou...ht key issues in forming partnerships and engage t... Minneapolis, MN (PRWEB) Nove...2010 Personalized Medicine Partnerships Conference...
(Date:11/5/2009)... -- DSM Pharmaceutical Products today announced th...ix, Saint Jean D,Illac, France, where DSM will be ...er for Galenix commercial products on a global bas...ness development opportunities co-marketing Galeni...h of Galenix in drug product development and clini...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...sive challenges and opportunities for micro and na...anufacturing of the fibres but in the control and ...workshop will focus on the many challenges of fibr...-of-the art surface chemical analysis, including S...damental effects of topography in SIMS and XPS, AF...
...Calif., May 14 VaxGen,Inc. (OTC Bulletin Board: V...guidance on its expected monthly cash expenditures...n on April 9, 2008. VaxGen expects that,its averag...kely to exceed,$1 million, made up of the followin...real estate and facility, estimated at 32% of m...
...dea Biosciences, Inc.,(Nasdaq: RDEA ) today annou...e Company,s lead mitogen-activated ERK kinase (MEK...W) 2008 in San Diego., The oral presentation det... 20, 2008 at 3:30 p.m. Pacific Time Abstract ...Inhibitor Ameliorates Murine Colitis Se...
Other Biology Technology:Micro and Nano Scale Characterization of Fibers 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 3Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2
(Date:11/6/2009)...Monell Center and the Chinese Academy of Sciences ...eting on Taste and Smell Research. Organized by Mo...ll be the first international meeting on taste and...f Executive Officer, American Association for the ...Science magazine, will open the meeting with a ple...
(Date:11/4/2009)...reluctant to officially endorse green tea as a can...about its protective effects, including results of...rch , a journal of the American Association for Ca...al cancer. , Vassiliki Papadimitrakopoulo, M.D....cic/Head and Neck Medical Oncology at the Universi...
(Date:11/4/2009)...ns out, hold the power to help militaries and muni...up toxic waste on test sites. , Compounds known ...k in World War II and have been used in military m... are often used to propel tank shells and act like...creased knowledge of their environmentally harmful...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Genomic research will enable greener cleanup of military explosive test sites 2Scientists use bed bugs own chemistry against them 47664 1Scientists use bed bugs own chemistry against them 47664 2Scientists use bed bugs own chemistry against them 47664 3Scientists use bed bugs own chemistry against them 47664 4Minnesota Healthcare Community to Build State of the Art Health Information Exchange 47660 1Minnesota Healthcare Community to Build State of the Art Health Information Exchange 47660 2New Program May Help Teens at High Risk for Depression 47656 1New Program May Help Teens at High Risk for Depression 47656 2New Program May Help Teens at High Risk for Depression 47656 3
...h team based at Massachusetts General Hospital (MG...ocess of RNA interference (RNAi), a powerful new r...nimals. They used the RNAi process itself to find ...echanism, which someday may help to fight human di...ce and is receiving early online release on the Sc...
... learn to imitate sounds that are not typical of t... of vocal learning in a non-primate terrestrial ma...urther supports the idea that vocal learning is im...ships among animals that separate and reunite over...ats. , Researchers from the Amboseli Trust for Ele...
...Inc. (Nasdaq: NGEN), developer of advanced diagnos....S. Patent No. 6,867,048, "Multiplexed Active Biol...e. The ,048 patent relates to a method of addressi... multiple rows and columns of a microarray. The pa... the voltage associated with each electrode in a l...
Other Biology News:Scientists identify genetic pathways essential to RNA interference 2Elephants imitate sounds as a form of social communication 2Nanogen Issued Patent for Electronic Microarray With Memory 2
ScriptCap m7G Capping System from EPICENTRE Biotechnologies
EXTRACTI-GEL D from Pierce Biotechnology, Inc.
...vides high speed and excellent temperature uniform...adient Thermocycler can be run without any modific...ock for 48 or 96 wells. In addition, modules for 3...le. The High Precision Smart Lid provides automati...
Agencourt SPRPlate D - Disc Magnet Plate from Agencourt Bioscience
Biology Products: